- Home
- PGZ vs LUNG Comparison
PGZ vs LUNG Comparison
Compare PGZ & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGZ
- LUNG
- Stock Information
- Founded
- PGZ 2012
- LUNG 1995
- Country
- PGZ United States
- LUNG United States
- Employees
- PGZ N/A
- LUNG N/A
- Industry
- PGZ Investment Managers
- LUNG Industrial Specialties
- Sector
- PGZ Finance
- LUNG Health Care
- Exchange
- PGZ Nasdaq
- LUNG Nasdaq
- Market Cap
- PGZ 68.9M
- LUNG 65.6M
- IPO Year
- PGZ N/A
- LUNG 2020
- Fundamental
- Price
- PGZ $10.56
- LUNG $1.70
- Analyst Decision
- PGZ
- LUNG Buy
- Analyst Count
- PGZ 0
- LUNG 7
- Target Price
- PGZ N/A
- LUNG $7.66
- AVG Volume (30 Days)
- PGZ 23.0K
- LUNG 570.9K
- Earning Date
- PGZ 01-01-0001
- LUNG 10-29-2025
- Dividend Yield
- PGZ 12.26%
- LUNG N/A
- EPS Growth
- PGZ N/A
- LUNG N/A
- EPS
- PGZ N/A
- LUNG N/A
- Revenue
- PGZ N/A
- LUNG $90,549,000.00
- Revenue This Year
- PGZ N/A
- LUNG $10.30
- Revenue Next Year
- PGZ N/A
- LUNG $14.72
- P/E Ratio
- PGZ N/A
- LUNG N/A
- Revenue Growth
- PGZ N/A
- LUNG 18.24
- 52 Week Low
- PGZ $8.46
- LUNG $1.47
- 52 Week High
- PGZ $10.59
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- PGZ 58.13
- LUNG 43.79
- Support Level
- PGZ $10.37
- LUNG $1.60
- Resistance Level
- PGZ $10.60
- LUNG $1.80
- Average True Range (ATR)
- PGZ 0.08
- LUNG 0.14
- MACD
- PGZ 0.01
- LUNG 0.04
- Stochastic Oscillator
- PGZ 82.61
- LUNG 36.67
About PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Germany, Singapore, South Korea, British Virgin Islands and more.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.